NRN1 and neoplasm: When combined with immune checkpoint inhibitors such as anti-PD-1 antibodies, NRN1-targeted therapy produced synergistic anti-tumor effects, suggesting that NRN1 inhibition could enhance the efficacy of existing immunotherapies.